Chronic Venous Disease Patients Showed Altered Expression of IGF-1/PAPP-A/STC-2 Axis in the Vein Wall

Miguel A. Ortega, Oscar Fraile-Martínez, Ángel Asúnsolo, Clara Martínez-Vivero, Leonel Pekarek, Santiago Coca, Luis G. Guijarro, Melchor Álvarez-Mon, Julia Buján, Natalio García-Honduvilla, and Felipe Sainz

1Department of Medicine and Medical Specialities, Faculty of Medicine and Health Sciences, University of Alcalá, Ramón y Cajal Institute of Sanitary Research (IRYCIS), University Center for the Defense of Madrid (CUD-ACD), Alcalá de Henares, 28047 Madrid, Spain
2Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcala, Ramón y Cajal Institute of Sanitary Research (IRYCIS), Alcala de Henares, Madrid, Spain
3Department of System Biology, Unit of Biochemistry and Molecular Biology (CIBEREHD), University of Alcala, Alcalá de Henares, Spain
4Immune System Diseases-Rheumatology, Oncology Service and Internal Medicine, University Hospital Príncipe de Asturias (CIBEREHD), Alcalá de Henares, Madrid, Spain
5Angiology and Vascular Surgery Service, Central University Hospital of Defense-UAH, Madrid, Spain

Correspondence should be addressed to Julia Buján; mjulia.bujan@uah.es

Received 20 July 2020; Accepted 2 December 2020; Published 15 December 2020

Academic Editor: Nicola Ielapi

Chronic venous disease (CVeD) has a remarkable prevalence, with an estimated annual incidence of 2%. It has been demonstrated how the loss of homeostatic mechanisms in the vein wall can take part in the physiopathology of CVeD. In this regard, it has been described how different axis, such as IGF-1/PAPP-A/STC-2 axis, may play an essential role in tissue homeostasis. The aim of this research is to study both genetic and protein expressions of the IGF-1/PAPP-A/STC-2 axis in CVeD patients. It is a cross-sectional study in which genetic (RT-qPCR) and protein (immunohistochemistry) expression analysis techniques were accomplished in saphenous veins from CVeD patients (n = 35) in comparison to individuals without vascular pathology (HV). Results show a significant increase in both genetic and protein expressions of PAPP-A and IGF-1, and a decrement STC-2 expression at the same time in CVeD patients. Our study is a pioneer for demonstrating that the expression of the different components of the IGF-1/PAPP-A/STC-2 axis is altered in CVeD patients. This fact can be a part of the loss of homeostatic mechanisms of the venous tissue. Further research should be destined to deepen into alterations of this axis, as well as to evaluate the usage of these components as therapeutic targets for CVeD.

1. Introduction

Chronic venous disease (CVeD) is described as a complex of disorders that affect the venous system, in which the presence of varicose veins (VV) implies the most important clinical manifestation [1]. It is a condition of great prevalence, more common amongst women and people aged 40-80 years, with an estimated annual incidence of 2% [2]. Amongst the risk factors associated with chronic venous disease, family history, aging, obesity, sedentarism, pregnancy, hormonal factors, and greater height are of great significance [3, 4]. Furthermore, CVeD implies a great cost to the health system,
especially in occidental societies [3]; consequently, it is necessary to keep expanding the knowledge of this disease towards a more appropriate management.

Usually, CVeD affects lower limbs, producing venous hypertension which the difficulties of the venous blood return to the heart, having been described as the valvular failure as a key factor of this process [5, 6]. Several authors propose that vein wall alterations can precede those processes. The mechanisms, described in regard to varicose veins, are of great importance: remodelling of the extracellular matrix [7], cellular hypoxia mechanisms [8], and multiple hemodynamic changes which, amongst other effects, conduct to secondary inflammation and oxidative stress, globally affecting to the different layers of the vein wall [9–11]. Therefore, it is known that a change in the normal homeostasis of the tissue conforming the vein wall occurs. Hereof, it has been described the potential determinant role of different axis such as the IGF-1/PAPP-A/STC-2 axis in tissue homeostasis [12].

Insulin-like growth factor-1 (IGF-1) is a growth factor implied in a great variety of metabolic processes of proliferation, growth, and cellular differentiation. Its levels are directly correlated to growth hormone (GH) levels, accomplishing all these effects through binding to IGF type 1 receptor (IGF1R) [13]. Insulin and IGF-1 share a great structural similarity, even though they bound to different receptors; cellular signalisation mediated by both of them is almost identical, highlighting their interaction with some factors like Akt or FoxO [14].

The role of the pregnancy-associated plasma protein A (PAPP-A) has been described as a negative regulator of the levels of IGFBPs, especially of IGFBP 2, 4, and 5. PAPP-A indirectly controls the effects of IGF-1 from the sectioning of IGFBPs, potentiating their cellular effects by increasing their bioavailability [15]. The role of PAPP-A in different vascular conditions, such as atherosclerosis, has been demonstrated, having been associated with an increase of inflammation and endothelial dysfunction along with proliferation and migration of smooth muscular cells [16], processes that are as well important for the pathogenesis of varicose veins. In addition, PAPP-A is a protein which can be determined in serum, where its usage as a biomarker for several vascular pathologies has been demonstrated [17–19]. On the other hand, stanniocalcin 2 (STC-2) has been depicted as an inhibitor of the proteolytic activity of PAPP-A, having been demonstrated multiple alterations of the PAPP-A/Stc-2 axis in a great variety of conditions, such as diabetes mellitus, cancer, and cardiovascular disorders [12].

Due to all of these reasons, this study is aimed at analyzing the expression of the different components of this axis in the vein wall from CVeD patients in comparison to the control patients without venous disease (HV) (45,000 [23,000-66,000] years old), p = 0.198. In the CVeD group, we had 22 women and 13 men, while in the HV group, we had 20 women and 7 men, p = 0.349. We observed that in CVeD patients, there were 22 patients with a family history of CVeD, while in HV, there were 18 patients, *p = 0.021.

The inclusion criteria were the following: women and men diagnosed with CVeD, with a body mass index (BMI) less than or equal to 25; with and without venous reflux in the greater saphenous vein; signed informed consent; and commitment to undergo follow-up during the pre- and postoperative periods, as well as to provide tissue samples. The exclusion criteria were patients with venous malformations or arterial insufficiency, patients without access to their clinical history, patients with pathologies that could affect the cardiovascular system (infectious diseases, diabetes, hypertension, and dyslipidemia), patients with toxic habits, and those uncertain of participating in the monitoring. The clinical diagnosis of CVeD and the evaluation of venous reflux were based on a noninvasive color Doppler ultrasound (7.5 to 10 MHz) of the superficial and deep vein systems. The saphenous vein segments for the HV group were verified during organ extraction for bypass surgery.

This study was conducted according to basic ethical principles (autonomy, harmless, benefit, and distributive justice); its development follows the standards of Good Clinical Practice and the principles enunciated in the last Declaration of Helsinki (2013) and the Oviedo Convention (1997). The project was approved by the ethics committee of the Gómez-Ulla Military Hospital (37/17).

2.2. Sample Processing. The totality of the mayor saphenous vein was extracted via saphenectomy. These fragments were introduced in two sterile tubes, one containing a RNA later solution (Ambion, Austin, TX, USA) and another containing MEM medium (Minimum Essential Medium) with 1% of antibiotic/antimycotic (Thermo Fisher Scientific, Waltham, MA, USA). Samples were processed in a Telstar AV 30/70 Müller class II 220 V 50 MHz laminar flow bell (Grupo Telstar SA, Terrassa, Spain) in a sterile environment. Samples collected in the RNA later solution were kept at -80°C until been processed for the analysis of gene expression. Samples preserved in MEM were used to carry out histological studies. Samples were washed and hydrated multiple times with MEM without antibiotic to remove the erythrocytes and isolate the venous tissue. Subsequently, the venous tissue was sectioned in fragments and samples were preserved in F13 fixative (60% ethanol, 20% methanol, 7% polyethylene glycol, and 13% distilled water). After the time needed to fix it, samples were dehydrated in increasing concentrations of alcohol and were subjected to paraffin inclusion process. Once the tissue is impregnated, a paraffin block is confectioned. From these blocks, fine five-micron sections were made in a HM 350s rotation microtome (Thermo Fisher Scientific, Waltham, MA, USA) and collected in slides impregnated with a 10% polylysine solution in order to accomplish the adherence of the sections to the slides.

2. Patients and Methods

2.1. Study Design. This is a cross-sectional study of 35 patients clinically diagnosed with CVeD (47,000 [27,000-68,000] years old) in comparison to 27 control patients without venous disease (HV) (45,000 [23,000-66,000] years old), p = 0.198. In the CVeD group, we had 22 women and 13 men, while in the HV group, we had 20 women and 7 men, p = 0.349. We observed that in CVeD patients, there were 22 patients with a family history of CVeD, while in HV, there were 18 patients, *p = 0.021.

The inclusion criteria were the following: women and men diagnosed with CVeD, with a body mass index (BMI) less than or equal to 25; with and without venous reflux in the greater saphenous vein; signed informed consent; and commitment to undergo follow-up during the pre- and postoperative periods, as well as to provide tissue samples. The exclusion criteria were patients with venous malformations or arterial insufficiency, patients without access to their clinical history, patients with pathologies that could affect the cardiovascular system (infectious diseases, diabetes, hypertension, and dyslipidemia), patients with toxic habits, and those uncertain of participating in the monitoring. The clinical diagnosis of CVeD and the evaluation of venous reflux were based on a noninvasive color Doppler ultrasound (7.5 to 10 MHz) of the superficial and deep vein systems. The saphenous vein segments for the HV group were verified during organ extraction for bypass surgery.

This study was conducted according to basic ethical principles (autonomy, harmless, benefit, and distributive justice); its development follows the standards of Good Clinical Practice and the principles enunciated in the last Declaration of Helsinki (2013) and the Oviedo Convention (1997). The project was approved by the ethics committee of the Gómez-Ulla Military Hospital (37/17).

2.2. Sample Processing. The totality of the mayor saphenous vein was extracted via saphenectomy. These fragments were introduced in two sterile tubes, one containing a RNA later solution (Ambion, Austin, TX, USA) and another containing MEM medium (Minimum Essential Medium) with 1% of antibiotic/antimycotic (Thermo Fisher Scientific, Waltham, MA, USA). Samples were processed in a Telstar AV 30/70 Müller class II 220 V 50 MHz laminar flow bell (Grupo Telstar SA, Terrassa, Spain) in a sterile environment. Samples collected in the RNA later solution were kept at -80°C until been processed for the analysis of gene expression. Samples preserved in MEM were used to carry out histological studies. Samples were washed and hydrated multiple times with MEM without antibiotic to remove the erythrocytes and isolate the venous tissue. Subsequently, the venous tissue was sectioned in fragments and samples were preserved in F13 fixative (60% ethanol, 20% methanol, 7% polyethylene glycol, and 13% distilled water). After the time needed to fix it, samples were dehydrated in increasing concentrations of alcohol and were subjected to paraffin inclusion process. Once the tissue is impregnated, a paraffin block is confectioned. From these blocks, fine five-micron sections were made in a HM 350s rotation microtome (Thermo Fisher Scientific, Waltham, MA, USA) and collected in slides impregnated with a 10% polylysine solution in order to accomplish the adherence of the sections to the slides.
2.3. Genetic Expression Study. The expression of the genes of interest was studied by real-time PCR method (RT-qPCR), in which the amount of cDNA was quantified in each of them. The RNA extraction was carried out by the guanidine-phenol-chloroform isothiocyanate method, following the procedure described by Ortega et al. [20]. Used primers were designed by the Primer-BLAST tool [21] and the AutoDimer application [22]. The StepOnePlus™ system was used with the relative standard curve method to carry out the quantitative PCR (qPCR). 5 μL from each sample, previously diluted in nucleases free water, was mixed with 10 μL of the intercalant agent IQ™ SYBR® Green Supermix (Bio-Rad Laboratories), 1 μL of forward primer, 1 μL of reverse primer, and 3 μL of free DNases and RNases water in a MicroAmp® 96-well plate (Applied Biosystems-Life Technologies), obtaining a final volume of 20 μL. Final results were normalized and compared to the GAPDH constitutive gene expression (Table 1). Data obtained from each gene were interpolated in a standard curve. In the 96-well plate, samples were triplicated and duplicated in a standard curve, and the two remaining wells were filled with negative controls.

2.4. Immunohistochemistry Studies. The antigen-antibody reaction was detected by the ABC method (avidin-biotin complex) with peroxidase or alkaline phosphatase as chromogen, in accordance with the protocol described by Ortega et al. [23]. The blocking of nonspecific binding sites was carried out with 3% bovine serum albumin (BSA) and PBS overnight at 4 °C (Table 2(a)). The incubation with the secondary antibody bounded to biotin was revealed with the ExtrAvidin®-Peroxidase avidin-biotin complex (Vector Laboratories, Burlingame, CA, USA). The reaction was detected by the ABC method (avidin-biotin complex) with peroxidase or alkaline phosphatase as chromogen, in accordance with the protocol described by Ortega et al. [23]. The blocking of nonspecific binding sites was carried out with 3% bovine serum albumin (BSA) and PBS overnight at 4 °C (Table 2(a)). The incubation with the secondary antibody bounded to biotin was revealed with the ExtrAvidin®-Peroxidase avidin-biotin complex (Vector Laboratories, Burlingame, CA, USA). The reaction was detected by the ABC method (avidin-biotin complex) with peroxidase or alkaline phosphatase as chromogen, in accordance with the protocol described by Ortega et al. [23]. The blocking of nonspecific binding sites was carried out with 3% bovine serum albumin (BSA) and PBS overnight at 4 °C (Table 2(a)). The incubation with the secondary antibody bounded to biotin was revealed with the ExtrAvidin®-Peroxidase avidin-biotin complex (Vector Laboratories, Burlingame, CA, USA). The reaction was detected by the ABC method (avidin-biotin complex) with peroxidase or alkaline phosphatase as chromogen, in accordance with the protocol described by Ortega et al. [23]. The blocking of nonspecific binding sites was carried out with 3% bovine serum albumin (BSA) and PBS overnight at 4 °C (Table 2(a)). The incubation with the secondary antibody bounded to biotin was revealed with the ExtrAvidin®-Peroxidase avidin-biotin complex (Vector Laboratories, Burlingame, CA, USA). The reaction was detected by the ABC method (avidin-biotin complex) with peroxidase or alkaline phosphatase as chromogen, in accordance with the protocol described by Ortega et al. [23]. The blocking of nonspecific binding sites was carried out with 3% bovine serum albumin (BSA) and PBS overnight at 4 °C (Table 2(a)). The incubation with the secondary antibody bounded to biotin was revealed with the ExtrAvidin®-Peroxidase avidin-biotin complex (Vector Laboratories, Burlingame, CA, USA). The reaction was detected by the ABC method (avidin-biotin complex) with peroxidase or alkaline phosphatase as chromogen, in accordance with the protocol described by Ortega et al. [23]. The blocking of nonspecific binding sites was carried out with 3% bovine serum albumin (BSA) and PBS overnight at 4 °C (Table 2(a)). The incubation with the secondary antibody bounded to biotin was revealed with the ExtrAvidin®-Peroxidase avidin-biotin complex (Vector Laboratories, Burlingame, CA, USA). The reaction was detected by the ABC method (avidin-biotin complex) with peroxidase or alkaline phosphatase as chromogen, in accordance with the protocol described by Ortega et al. [23]. The blocking of nonspecific binding sites was carried out with 3% bovine serum albumin (BSA) and PBS overnight at 4 °C (Table 2(a)). The incubation with the secondary antibody bounded to biotin was revealed with the ExtrAvidin®-Peroxidase avidin-biotin complex (Vector Laboratories, Burlingame, CA, USA). The reaction was detected by the ABC method (avidin-biotin complex) with peroxidase or alkaline phosphatase as chromogen, in accordance with the protocol described by Ortega et al. [23]. The blocking of nonspecific binding sites was carried out with 3% bovine serum albumin (BSA) and PBS overnight at 4 °C (Table 2(a)). The incubation with the secondary antibody bounded to biotin was revealed with the ExtrAvidin®-Peroxidase avidin-biotin complex (Vector Laboratories, Burlingame, CA, USA). The reaction was detected by the ABC method (avidin-biotin complex) with peroxidase or alkaline phosphatase as chromogen, in accordance with the protocol described by Ortega et al. [23]. The blocking of nonspecific binding sites was carried out with 3% bovine serum albumin (BSA) and PBS overnight at 4 °C (Table 2(a)).

An incubation with the ExtrAvidin®-Peroxidase aavdinperoxidase conjugate (Sigma-Aldrich, St. Louis, MO, USA) was carried out for 60 minutes at room temperature (diluted to 1:1200 on PBS). The incubation was revealed with the diaminobenzidine chromogenic substrate (DAB Kit, SK-4100) (Vector Laboratories, Burlingame, CA, USA). The chromogenic substrate was prepared immediately before exposure (5 mL of distilled water, 2 drops of tampon, 4 drops of DAB, and 2 drops of hydrogen peroxide). This technique allows a brown colored stain. In order to obtain contrast with the nucleus stain, incubation in Carazzi’s haematoxylin was carried out for 5-15 minutes mount in aqueous medium with Plasdone. In every genetic study, sections from the same tissue were used as negative control, in which the incubation with the primary antibody was substituted with incubation with blocking solution.

2.5. Statistical Analysis in Interpretation of Results. For the purpose of the statistical analysis, the GraphPad Prism® 5.1 statistical program was used, and the Mann–Whitney U and χ² Pearson’s test were applied. The data are expressed as the median with interquartile range (IQR). Error bars on the figures are expressed with IQR. The significance values were set at *p < 0.05, **p < 0.005, and ***p < 0.001.

The preparations were examined under a Zeiss Axioskop optical microscope (Carl Zeiss, Oberkochen, Germany).

Given the important role of the proteins involved, the assessment of the histological results was performed by the intensity of expression for immunohistochemical staining with a score of 1 to 3. Henceforth, histological samples from patients were classified as negative (0) or positive (1-3) IRS score method [24]. For each established group of subjects, 7 randomly selected microscopy fields were examined in each of the 5 sections. Subjects were classified as positive when the average proportion of the labelled sample was greater or equal to 5% of the total sample. This was done by calculating the total percentage of tissue marked in each microscopy field to obtain the value of mean for the study sample as described by Cristóbal et al. [25]. The observation and quantification of the samples were independently performed by two investigators.

3. Results

3.1. Increased Expression of IGF-1 in the Vein Wall of CVeD Patients. Genetic expression study of IGF-1 showed no significant differences between the study groups, although it did show an upward trend in CVeD patients (CVeD = 2.250 [0.630 – 4.013] vs. HV = 2.014 [1.036 – 3.068], p = 0.5559) (Figure 1(a)).

In contrast, a significant increase in the IGF-1 protein expression was observed in the vein wall from CVeD patients (CVeD = 2.000 [0.500 – 3.000] vs. HV = 1.000 [0.000 – 2.250], *p = 0.0104). The microscopic analysis showed how the expression of IGF-1 was located in the three tunics of the vein wall (Figure 1(b)). An increased intensity was observed in the smooth muscular fibres and extracellular matrix of the vein wall from CVeD patients (Figure 1(c)).

3.2. CVeD Patients Show a Significant Increase of PAPP-A. Genetic expression study of PAPP-A in the vein wall showed a significant increase in CVeD patients in comparison to HV (CVeD = 10.230 [7.846 – 11.726] vs.HV = 9.089 [7.324 – 10.013], **p = 0.0029) (Figure 2(a)).

Protein expression of PAPP-A was significantly increased in the vein wall from CVeD patients (CVeD = 1.500 [0.250 – 3.000] vs.HV = 0.500 [0.000 – 1.500], ***p = 0.0002). PAPP-A was located in the three tunics of the vein wall from CVeD patients (Figure 2(b)). It is worth noting how the expression of PAPP-A was intensely located in the smooth muscular fibres of the vein wall from these patients (Figure 2(c)).

3.3. Significant Decrease in the Expression of STC-2 amongst CVeD Patients. A significant decrease in the genetic expression of STC-2 was observed amongst CVeD patients in comparison to HV by RT-qPCR (CVeD = 7.190 [3.296 – 11.324] vs HV = 10.845 [9.079 – 13.389], ***p < 0.0001) (Figure 3(a)).

Protein expression study performed by immunohistochemistry techniques showed in a similar fashion a significant decrease (CVeD = 0.250 [0.000 – 1.000] vs HV = 1.000 [0.000 – 2.500], *p = 0.0056). The microscopic analysis showed SCT-2 was mainly located in the medium tunic of the vein wall from HV patients (Figure 3(c), asterisk).
4. Discussion

CVeD causes a severe alteration in the homeostasis of the vein wall, unchaining the activation of both cellular and systemic responses [11]. It has been found that this process is associated with different pathologic mechanisms which are key in the development of the disease such as an increase in the process of apoptosis and cellular death [26], deregulation in the synthesis of some cytokines [27], and even with some cell signaling pathways and changes in the extracellular matrix [28].

The impact that IGF-1 signaling can have on the aging process has long been known. Various animal models ranging from yeasts to human beings have demonstrated that lower levels of IGF-1 are associated with an increased longevity and a deceleration of the aging process [29]. However, it is known that the effects and levels of IGF-1 both at a physiologic level and a pathologic level depend on tissue, gender, and age of the subject [30], and it has also been demonstrated how the alteration of its signaling is associated with the appearance of several aging-associated diseases [31].

Table 1: Primer sequences used in RT-qPCR and temperature (Tm).

| Gene   | Sec. Fwd (5′ → 3′)             | Sec. Rev (5′ → 3′)                    | Tm |
|--------|--------------------------------|--------------------------------------|----|
| GAPDH  | GGAAGGTGAAGGTCGGAGTCA          | GTCATTGATGGCAAACATATCCACT           | 60 |
| IGF-1  | GCTCTTCAGTTGCTGTGTTG          | CGCAATACATCTTCAGCCTC                | 69 |
| STC-2  | GCTTCGTCCTCCCTCAC             | GATCCAGGAGGTCCGACAC                | 51 |
| PAPP-A | CCCAGGCAGTCAGATCATCTTC        | AGCTGCCCTCAGTTGA                  | 52 |

Table 2: Primary (A) and secondary (B) antibodies used in the immunohistochemical studies performed, showing the dilutions used and the protocol specifications.

(a)

| Antigen | Species | Dilution | Provider          | Protocol specifications                                           |
|---------|---------|----------|-------------------|------------------------------------------------------------------|
| IGF-1   | Rabbit  | 1 : 100  | Abcam (ab263903)  | 10 mM sodium citrate, pH = 6 before incubation with blocking solution |
| PAPP-A  | Mouse   | 1 : 500  | Abcam (ab52030)   | 0.1% Triton in PBS, 10 minutes before incubation with blocking solution |
| STC-2   | Rabbit  | 1 : 300  | Abcam (ab261915)  |                                                                  |

(b)

| Antigen | Species | Dilution | Provider          | Protocol specifications |
|---------|---------|----------|-------------------|-------------------------|
| IgG (mouse) | Goat    | 1 : 300  | Sigma (F2012/045k6072) | —                       |
| IgG (rabbit)  | Mouse   | 1 : 1000 | Sigma (RG-96/B5283)         | —                       |

4. Discussion

CVeD causes a severe alteration in the homeostasis of the vein wall, unchaining the activation of both cellular and systemic responses [11]. It has been found that this process is associated with different pathologic mechanisms which are key in the development of the disease such as an increase in the process of apoptosis and cellular death [26], deregulation in the synthesis of some cytokines [27], and even with some cell signaling pathways and changes in the extracellular matrix [28].

The impact that IGF-1 signaling can have on the aging process has long been known. Various animal models ranging from yeasts to human beings have demonstrated that lower levels of IGF-1 are associated with an increased longevity and a deceleration of the aging process [29]. However, it is known that the effects and levels of IGF-1 both at a physiologic level and a pathologic level depend on tissue, gender, and age of the subject [30], and it has also been demonstrated how the alteration of its signaling is associated with the appearance of several aging-associated diseases [31].

Previous studies have shown the existence of an increase in IGF-1 levels and its receptor, IGF-1R in varicose veins, in comparison to control veins, thus demarcating the important role it can play in the pathogenesis of the disease [32]. Moreover, the role of IGF-1 regarding the activation of the PI3K/Akt/mTOR pathway has been demonstrated and how these components were jointly involved in aging process, as well as its associated diseases [33]. Jia et al. [34] reported how IGF-1-mediated signaling promoted the phosphorylation of PI3K and Akt in smooth muscular cells of saphenous veins, promoting their proliferation in vitro. Along the same lines, our previous results showed that the PI3K/Akt/mTOR pathway was altered in CVeD patients, showing a direct association between greater involvement of this pathway and both premature and asynchronous aging of the venous tissue [28]. There are also more studies which show how IGF-1 promotes the activation of different signaling pathways, such as MAPK [35]. It has been demonstrated the existence of a greater activation of some components in this pathway, such as ERK1/2 in CVeD patients, especially in those who present venous reflux [36]. Our results show how the increase of IGF-1 could be associated with these statements, collaborating with the detriment suffered by venous tissue.

Amongst the different regulatory mechanisms of IGF-1, pregnancy-associated plasma protein A (PAPP-A) is one of the most studied elements vitally important in the regulation of this factor [37]. Although PAPP-A was initially found and identified in trophoblasts of the placenta from pregnant women, it has been demonstrated how it is also expressed in a vast range of cells and tissues, including fibroblasts and smooth muscular cells, both of great relevance in the pathogenesis of the varicose vein [7, 38].

PAPP-A is a protein which undergoes very strict regulation in the cell. On the one hand, it is known that its expression can be modulated by the synthesis of some proinflammatory cytokines, especially by IL-1β and TNF-α [37]. The role of inflammation in CVeDs has been extensively studied. It is known that the inflammatory process accompanies the development of the diseases as a consequence of the tissue damage associated with the situation of venous hypertension and valvular incompetence, observing an increase in leukocyte infiltration, as well as in the synthesis of proinflammatory cytokines [39]. It has been demonstrated that in atheromatous coronary arteries, this macrophage-mediated proinflammatory environment induces the
expression and secretion of PAPP-A in both endothelial and smooth muscular cells [40]. In addition, as previously mentioned, PAPP-A increases the bioavailability of IGF-1 and the signaling mediated by its receptor in an autocrine and paracrine manner in the tissue [41], having been described the role of IGF-1 in the stimulation of the inflammatory response and the synthesis of cytokines [42].

Our results suggest that in the vein wall from CVeD patients, the inflammation associated with this condition could be acting similarly by increasing the expression of PAPP-A, in a positive feedback process. This fact is involved in promoting other main pathogenic processes, such as endothelial dysfunction [43].

On the other hand, there are different mechanisms which negatively regulate PAPP-A levels in the cell, those that are carried out by a series of proteins depicted as stanniocalcins 1 and 2 [44]. Interestingly, it is known that Stc-2, contrarily to Stc-1, covalently bounds to PAPP-A, performing both essential functions in the regulation of calcium levels and cellular response to different conditions as oxidative stress or endoplasmic reticulum stress, hence being fundamental in cellular homeostasis [45, 46]. We previously demonstrated the existence of an increase in oxidative stress damage markers and in the lipidic peroxidation process in CVeD patients [11]. Our results show how decreasing Stc-2 levels could support this fact, in addition to implying the loss of

**Figure 1:** (a) Expression of mRNA for IGF-1 in CVeD (chronic venous disease) and HV (healthy controls) in arbitrary units. (b–d) Images showing immunostaining for IGF-1 in CVD patients in the three venous wall robes (asterisk) and CV. I: intimate robe; M: middle robe; A: adventitious robe.

**Figure 2:** (a) Expression of mRNA for PAPP-A in CVeD (chronic venous disease) and HV (healthy controls) in arbitrary units. (b–d) Images showing immunostaining for PAPP-A in CVD patients in the three tunics of the venous wall (asterisk) and CV. I: intimate robe; M: middle robe; A: adventitious robe. **p < 0.005**.
an inhibition mechanism of the proteolytic activity of PAPP-A and, therefore, of the signaling regulation mediated by IGF-1 in the venous tissue that appears in CVeD patients.

The analysis of the serum levels of these components and their possible use as biomarkers is also currently in progress. It is important to note that circulating PAPP-A can be found in 2 different forms: a first form associated with pregnancy, covalently bound to the proteolytically inactive eosinophil major basic protein (proMPB), and a second form produced by vascular cells that are not covalently bound to proMBP and that do exhibit proteolytic activity, which this distinction is being important for its measurement and interpretation under different conditions [47]. The presence of Stc-2 in serum has also been identified, as well as IGFBP-4, which is regulated by PAPP-A [48]. Although PAPP-A also modulates other IGFBPs, such as IGFBP 2 and 5, IGFBP-4 exclusively appears to be regulated by the proteolytic activity of PAPP-A. Taking into account all of these reasons, the Stc-2/PAPP-A/IGF-1 axis is necessary to know all the physiopathologic mechanisms involved in vascular diseases [49–54].

5. Conclusions

Our study is pioneering in showing how CVeD patients have a significant increase of PAPP-A expression in their vein wall. These markers may be quite relevant as CVeD markers. Further studies should be oriented to the measurement and assessment of different components of this axis which may serve as serum biomarkers in venous disease patients. However, our study is the first to highlight the presence and importance of IGF-1/PAPP-A/STC-2 markers in CVeD.
Data Availability
The data used to support the findings of the present study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
Miguel A Ortega and Oscar Fraile-Martinez contributed equally in this work. Julia Buján, Natalio García-Honduvilla, and Felipe Sainz shared senior authorship in this work.

Acknowledgments
This work was supported by grants from the National Institute of Health Carlos III (FIS-PI18/00912 and B2017/BMD-3804 MITIC-CM).

References
[1] R. T. Eberhardt and J. D. Raffetto, “Chronic venous insufficiency,” *Circulation*, vol. 130, no. 4, pp. 333–346, 2014.
[2] E. Rabe, G. Berboth, and F. Pannier, “Epidemiology of chronic venous diseases,” *Wiener Medizinische Wochenschrift*, vol. 166, no. 9–10, pp. 260–263, 2016.
[3] M. McArdle and E. A. Hernandez-Vila, “Management of chronic venous disease,” *Texas Heart Institute Journal*, vol. 44, no. 5, pp. 347–349, 2017.
[4] M. A. Ortega, M. A. Saez, O. Fraile-Martinez et al., “Increased angiogenesis and lymphangiogenesis in the placental villi of women with chronic venous disease during pregnancy,” *International Journal of Molecular Sciences*, vol. 21, no. 7, p. 2487, 2020.
[5] J. V. White and C. Ryjewski, “Chronic venous insufficiency,” *Perspectives in Vascular Surgery and Endovascular Therapy*, vol. 17, no. 4, pp. 319–327, 2005.
[6] Y. J. Youn and J. Lee, “Chronic venous insufficiency and varicose veins of the lower extremities,” *The Korean Journal of Internal Medicine*, vol. 34, no. 2, pp. 269–283, 2019.
[7] Y. Chen, W. Peng, J. D. Raffetto, and R. A. Khalil, “Matrix metalloproteinases in remodeling of lower extremity veins and chronic venous disease,” *Progress in Molecular Biology and Translational Science*, vol. 147, pp. 267–299, 2017.
[8] M. A. Ortega, B. Romero, Á. Asúnsolo et al., “Behavior of smooth muscle cells under hypoxic conditions: possible implications on the varicose vein endothelium,” *BioMed Research International*, vol. 2018, Article ID 7156150, 9 pages, 2018.
[9] J. D. Raffetto and F. Mannello, “Pathophysiology of chronic venous disease,” *Int Angiol*, vol. 33, no. 3, pp. 212–221, 2014.
[10] D. Saribal, E. M. Kanber, F. S. Hoçaoglu-Emre, and M. C. Akyolcu, “Effects of the oxidative stress and genetic changes in varicose vein patients,” *Phlebology*, vol. 34, no. 6, pp. 406–413, 2019.
[11] M. A. Ortega, B. Romero, Á. Asúnsolo et al., “Patients with incompetent valves in chronic venous insufficiency show increased systematic lipid peroxidation and cellular oxidative stress markers,” *Oxidative Medicine and Cellular Longevity*, vol. 2019, Article ID 5164576, 9 pages, 2019.
[12] R. Hjortebjerg, “IGFBP-4 and PAPP-A in normal physiology and disease,” *Growth Hormone & IGF Research*, vol. 41, pp. 7–22, 2018.
[13] Martinelli CE Jr, R. J. Custódio, and M. H. Aguiar-Oliveira, “Physiology of the GH-IGF axis,” *Arquivos Brasileiros de Endocrinologia e Metabologia*, vol. 52, no. 5, pp. 717–725, 2008.
[14] T. Sasako and K. Ueki, “Insulin/IGF-1 signaling and aging,” *Nihon Rinsho*, vol. 74, no. 9, pp. 1435–1440, 2016.
[15] P. Monget, “La PAPP-A et le systeme des IGFs,” *Annales d’endocrinologie*, vol. 77, no. 2, pp. 90–96, 2016.
[16] X. H. Yu, L. H. He, J. H. Gao, D. W. Zhang, and X. L. Zheng, “Pregnancy-associated plasma protein-A in atherosclerosis: molecular marker, mechanistic insight, and therapeutic target,” *Atherosclerosis*, vol. 278, pp. 250–258, 2018.
[17] M. Lodh, B. Goswami, A. Parida, S. Patra, and A. Saxena, “Assessment of serum leptin, pregnancy-associated plasma protein A and CRP levels as indicators of plaque vulnerability in patients with acute coronary syndrome,” *Cardiovascular Journal of Africa*, vol. 23, no. 6, pp. 330–335, 2012.
[18] H. Duan, G. Zhao, B. Xu, S. Hu, and J. Li, “Maternal serum PLGF, PAPP-A, β-hCG and AFP levels in early second trimester as predictors of preeclampsia,” *Clinical Laboratory*, vol. 63, no. 05, pp. 921–925, 2017.
[19] H. Gutiérrez-Leonard, E. Martínez-Lara, A. E. Fierro-Macias, V. M. Mena-Burciaga, and M. D. Ronquillo-Sánchez, “Pregnancy-associated plasma protein-A (PAPP-A) as a possible biomarker in patients with coronary artery disease,” *Ir J Med Sci*, vol. 186, no. 3, pp. 597–605, 2017.
[20] M. A. Ortega, B. Romero, Á. Asúnsolo et al., “Pregnancy-associated venous insufficiency course with placental and systemic oxidative stress,” *Journal of Cellular and Molecular Medicine*, vol. 24, no. 7, pp. 4157–4170, 2020.
[21] M. A. Ortega, Á. Asúnsolo, M. J. Álvarez-Rocha et al., “Remodelling of collagen fibres in the placenta of women with venous insufficiency during pregnancy,” *Histol Histopathol*, vol. 33, no. 6, pp. 567–576, 2018.
[22] P. M. Vallone and J. M. Butler, “AutoDimer: a screening tool for primer-dimer and hairpin structures,” *BioTechniques*, vol. 37, no. 2, pp. 226–231, 2004.
[23] M. A. Ortega, M. A. Saez, Á. Asúnsolo et al., “Upregulation of VEGF and PEDF in placenta of women with lower extremity venous insufficiency during pregnancy and its implication in villous calcification,” *BioMed Research International*, vol. 2019, Article ID 5320902, 8 pages, 2019.
[24] P. Sanmartin-Salinas, M. V. Toledo-Lobo, F. Nogueiras-Fragas, M. E. Fernández-Contreras, and L. G. Gujjarro, “Overexpression of insulin receptor substrate-4 is correlated with clinical staging in colorectal cancer patients,” *Journal of Molecular Histology*, vol. 49, no. 1, pp. 39–49, 2018.
[25] L. Cristóbal, M. A. Ortega, Á. Asúnsolo et al., “Human skin model for mimic dermal studies in pathology with a clinical implication in pressure ulcers,” *Histol Histopathol*, vol. 33, no. 9, pp. 959–970, 2018.
[26] J. Buján, J. A. Jiménez-Cossio, F. Jurado et al., “Evaluation of the smooth muscle cell component and apoptosis in the varicose vein wall,” *Histol Histopathol*, vol. 15, no. 3, pp. 745–752, 2000.
[27] G. Pascual, C. Mendieta, N. García-Honduvilla, C. Corrales, J. M. Bellón, and J. Buján, “TGF-beta1 upregulation in the aging varicose vein,” *Journal of Vascular Research*, vol. 44, no. 3, pp. 192–201, 2007.
[28] M. A. Ortega, Á. Asınssolo, J. Leal et al., “Implication of the PI3K/Akt/mTOR pathway in the process of incompetent valves in patients with chronic venous insufficiency and the relationship with aging,” *Oxidative Medicine and Cellular Longevity*, vol. 2018, Article ID 1495170, 14 pages, 2018.

[29] L. Fontana, L. Partridge, and V. D. Longo, “Extending healthy life span—from yeast to humans,” *Science*, vol. 328, no. 5976, pp. 321–326, 2010.

[30] N. M. Ashpole, S. Logan, A. Yabluchanskiy et al., “IGF-1 has sexually dimorphic, pleiotropic, and time-dependent effects on healthspan, pathology, and lifespan,” *Geroscience*, vol. 39, no. 2, pp. 129–145, 2017.

[31] V. N. Anismov and A. Bartke, “The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer,” *Critical Reviews in Oncology/Hematology*, vol. 87, no. 3, pp. 201–223, 2013.

[32] M. Bruczkó-Goralewska, L. Romanowicz, J. Bączyk, M. Wolańska, K. Sobolewski, and R. Kowalewski, “Peptide growth factors and their receptors in the vein wall,” *Journal of Investigative Medicine*, vol. 67, no. 8, pp. 1149–1154, 2019.

[33] S. C. Johnson, “Nutrient sensing, signaling and ageing: the role of IGF-1 and mTOR in ageing and age-related disease,” *Sub-Cellular Biochemistry*, vol. 90, pp. 49–97, 2018.

[34] G. Jia, A. K. Mitra, D. M. Gangahar, and D. K. Agraval, “Insulin-like growth factor-1 induces phosphorylation of PI3K-Akt/PKB to potentiate proliferation of smooth muscle cells in human saphenous vein,” *Experimental and Molecular Pathology*, vol. 89, no. 1, pp. 20–26, 2010.

[35] Z. Wu, Y. Yu, L. Niu, A. Fei, and S. Pan, “IGF-1 protects tubular epithelial cells during injury via activation of ERK/MAPK signaling pathway,” *Scientific Reports*, vol. 6, no. 1, 2016.

[36] M. A. Ortega, Á. Asínssolo, B. Romero et al., “Unravelling the role of MAPks (ERK1/2) in venous reflux in patients with chronic venous disorder,” *Cells, Tissues, Organs*, vol. 206, no. 4–5, pp. 272–282, 2019.

[37] C. A. Conover and C. Oxvig, “PAPP-A: a promising therapeutic target for healthy longevity,” *Aging Cell*, vol. 16, no. 2, pp. 205–209, 2017.

[38] C. Oxvig, “The role of PAPP-A in the IGF system: location, location, location,” *J Cell Commun Signal.*, vol. 9, no. 2, pp. 177–187, 2015.

[39] D. Ligi, L. Croce, and F. Mannello, “Chronic venous disorders: the dangerous, the good, and the diverse,” *International Journal of Molecular Sciences*, vol. 19, no. 9, p. 2544, 2018.

[40] C. A. Conover, S. C. Harrington, and L. K. Bale, “Differential regulation of pregnancy associated plasma protein-A in human coronary artery endothelial cells and smooth muscle cells,” *Growth Hormone & IGF Research*, vol. 18, no. 3, pp. 213–220, 2008.

[41] J. H. Mikkelsen, Z. T. Resch, B. Kalra et al., “Indirect targeting of IGF receptor signaling in vivo by substrate-selective inhibition of PAPP-A proteolytic activity,” *OncoTarget*, vol. 5, no. 4, pp. 1014–1025, 2014.

[42] V. H. Heemskerk, M. A. Daemen, and W. A. Buurman, “Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation,” *Cytokine & Growth Factor Reviews*, vol. 10, no. 1, pp. 5–14, 1999.

[43] R. Castro-Ferreira, R. Cardoso, and A. Leite-Moreira, “The role of endothelial dysfunction and inflammation in chronic venous disease,” *Annals of Vascular Surgery*, vol. 46, pp. 380–393, 2018.

[44] M. R. Jepsen, S. Krøverpris, J. A. Bøtkjær, M. L. Wissing, and C. Y. Andersen, “The proteolytic activity of pregnancy-associated plasma protein-A is potentially regulated by stanniocalcin-1 and -2 during human ovarian follicle development,” *Human Reproduction*, vol. 31, no. 4, pp. 866–874, 2016.

[45] B. H. Yeung, A. Y. Law, and C. K. Wong, “Evolution and roles of stanniocalcin,” *Molecular and Cellular Endocrinology*, vol. 349, no. 2, pp. 272–280, 2012.

[46] M. R. Jepsen, S. Krøverpris, J. H. Mikkelsen et al., “Stanniocalcin-2 inhibits mammalian growth by proteolytic inhibition of the insulin-like growth factor axis,” *The Journal of Biological Chemistry*, vol. 290, no. 6, pp. 3430–3439, 2015.

[47] C. A. Conover, “Key questions and answers about pregnancy-associated plasma protein-A,” *Trends in Endocrinology and Metabolism*, vol. 23, no. 5, pp. 242–249, 2012.

[48] G. Panagiotou, A. D. Anastasialakis, G. Kynigopoulos, and E. C. Skouvaklidou, “Physiological parameters regulating circulating levels of the IGFBP-4/stanniocalcin-2/PAPP-A axis,” *Metabolism*, vol. 75, pp. 16–24, 2017.

[49] U. S. Espelund, M. Bjerre, R. Hjortebjerg, T. R. Rasmussen, A. Lundby, A. Hoechli et al., “Insulin-like growth factor bioactivity, stanniocalcin-2, pregnancy-associated plasma protein-A, and IGF-binding protein-4 in pleural fluid and serum from patients with pulmonary disease,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 102, no. 9, pp. 3526–3534, 2017.

[50] G. Cediel, F. Rueda, C. Oxvig et al., “Prognostic value of the stanniocalcin-2/PAPP-A/IGFBP-4 axis in ST-segment elevation myocardial infarction,” *Cardiovasc Diabetol*, vol. 17, no. 1, pp. ?, 2018.

[51] G. Piazza, “Varicose veins,” *Circulation*, vol. 130, no. 7, pp. 582–587, 2014.

[52] E. Fukaya, A. M. Flores, D. Lindholm et al., “Clinical and genetic determinants of varicose veins,” *Circulation*, vol. 138, no. 25, pp. 2869–2880, 2018.

[53] N. García-Hondonville, Á. Asínssolo, M. A. Ortega et al., “Increase and redistribution of sex hormone receptors in premenopausal women are associated with varicose vein remodelling,” *Oxidative Medicine and Cellular Longevity*, vol. 2018, Article ID 1495170, 14 pages, 2018.

[54] S. Mahapatra, P. Ramakrishna, B. Gupta, A. Anusha, and M. A. Para, “Correlation of obesity & comorbid conditions with chronic venous insufficiency: results of a single-centre study,” *The Indian Journal of Medical Research*, vol. 147, no. 5, pp. 471–476, 2018.

[55] J. Taylor and C. W. Hicks, “The hemodynamic effects of pregnancy on the lower extremity venous system,” *Journal of Vascular Surgery. Venous and Lymphytic Disorders*, vol. 6, no. 2, pp. 246–255, 2018.